Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer
出版年份 2015 全文链接
标题
Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer
作者
关键词
-
出版物
ONCOGENE
Volume 35, Issue 15, Pages 1877-1887
出版商
Springer Nature
发表日期
2015-08-10
DOI
10.1038/onc.2015.287
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
- (2015) Milan Bruncko et al. JOURNAL OF MEDICINAL CHEMISTRY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival
- (2015) Nai Yang Fu et al. NATURE CELL BIOLOGY
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
- (2015) A. N. Hata et al. Cancer Discovery
- Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?
- (2015) Michelle M. Williams et al. Oncotarget
- Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy
- (2014) Ivana Bozovic-Spasojevic et al. BREAST
- MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab
- (2014) Anamarija M. Perry et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
- (2014) G. L. Kelly et al. GENES & DEVELOPMENT
- Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer
- (2014) Corey J. Langer et al. LUNG CANCER
- Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
- (2014) Fariba Némati et al. PLoS One
- Targeting BCL2 for the Treatment of Lymphoid Malignancies
- (2014) Mary Ann Anderson et al. SEMINARS IN HEMATOLOGY
- Many players in BCL-2 family affairs
- (2014) Tudor Moldoveanu et al. TRENDS IN BIOCHEMICAL SCIENCES
- Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy
- (2014) Jung Eun Choi et al. TUMOR BIOLOGY
- Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1)
- (2014) Chao Fang et al. ACS Medicinal Chemistry Letters
- Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
- (2014) Zhi-Fu Tao et al. ACS Medicinal Chemistry Letters
- Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings
- (2013) T. M. A. Abdel-Fatah et al. ANNALS OF ONCOLOGY
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
- (2013) François Vaillant et al. CANCER CELL
- Analysis of the Potent Prognostic Factors in Luminal-Type Breast Cancer
- (2013) Han-Sung Kim et al. Journal of Breast Cancer
- Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-XL
- (2013) Brad E. Sleebs et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Potent Mcl-1/Bcl-xL Dual Inhibitors by Using a Hybridization Strategy Based on Structural Analysis of Target Proteins
- (2013) Yuta Tanaka et al. JOURNAL OF MEDICINAL CHEMISTRY
- Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer
- (2013) Jeffrey B. Smerage et al. Molecular Oncology
- Structure-guided design of a selective BCL-XL inhibitor
- (2013) Guillaume Lessene et al. Nature Chemical Biology
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Prognostic value of bcl-2 expression among women with breast cancer in Libya
- (2013) Eramah Ermiah et al. TUMOR BIOLOGY
- The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
- (2013) Matthew J. Ellis et al. Cancer Discovery
- Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy
- (2012) Mathilde S. Larsen et al. ACTA ONCOLOGICA
- Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
- (2012) D. Merino et al. BLOOD
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study
- (2012) C. Visco et al. HAEMATOLOGICA
- Prognostic influence of BCL2 expression in breast cancer
- (2012) Ki-Tae Hwang et al. INTERNATIONAL JOURNAL OF CANCER
- ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
- (2012) Ji-Yu Li et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design
- (2012) Anders Friberg et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
- (2012) R W Rooswinkel et al. Cell Death & Disease
- Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
- (2011) G. Sonpavde et al. ANNALS OF ONCOLOGY
- Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad
- (2011) Shutao Yin et al. APOPTOSIS
- GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1
- (2011) Lin Zheng et al. CANCER LETTERS
- Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between “triple-negative” and non–“triple-negative” tumors
- (2011) Kareem Tawfik et al. HUMAN PATHOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer
- (2011) H Raza Ali et al. JOURNAL OF PATHOLOGY
- Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
- (2011) Neal Ready et al. Journal of Thoracic Oncology
- A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer
- (2011) Maria Q. Baggstrom et al. Journal of Thoracic Oncology
- The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
- (2011) J. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
- (2011) S. R. Oakes et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Five-Gene Model Predicts Clinical Outcome in ER+/PR+, Early-Stage Breast Cancers Treated with Adjuvant Tamoxifen
- (2011) Daniel Alan Kerr et al. Hormones & Cancer
- BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
- (2010) S-J Dawson et al. BRITISH JOURNAL OF CANCER
- A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
- (2010) T. O. Nielsen et al. CLINICAL CANCER RESEARCH
- Forced involution of the functionally differentiated mammary gland by overexpression of the pro-apoptotic protein bax
- (2010) Edmund B. Rucker et al. GENESIS
- Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer
- (2010) Tarek MA Abdel-Fatah et al. JOURNAL OF PATHOLOGY
- Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer
- (2009) J. Rom et al. ANNALS OF ONCOLOGY
- Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer
- (2009) Grace M Callagy et al. BMC CANCER
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Alteration of the Mitochondrial Apoptotic Pathway Is Key to Acquired Paclitaxel Resistance and Can Be Reversed by ABT-737
- (2008) O. Kutuk et al. CANCER RESEARCH
- Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer
- (2008) S. L. Moulder et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now